Published in Immunotherapy Weekly, July 1st, 2009
"While the former might impair antitumor cellular immunity, a consideration for immunotherapy, the latter could cause 10q-maintaining tumor patients to experience comparatively higher rates of bacterial infections, a source of morbidity and mortality in glioblastoma patients. We retrospectively reviewed 58 glioblastoma...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
Source: Immunotherapy Weekly (2009-07-01)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.